This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F20.2 (catatonic schizophrenia) | Special Copayment Reduction: V161 (severe intractable disease, copayment reduction for 5 years after registration) |
| B. Synonyms | Catatonic type schizophrenia, catatonic stupor, schizophrenic catalepsy, schizophrenic catatonia, schizophrenic flexibilitas cerea |
| C. Adult onset | Possibility of first onset in adulthood Present — catatonic schizophrenia mainly begins at ages 15-35, and onset in early adulthood (ages 20-35) is common. The catatonia syndrome itself can occur at any age, but catatonia due to schizophrenia is prominent in adolescence to early adulthood. |
| 1. History | 1874: Kahlbaum first describes catatonia → included by Kraepelin as a subtype of dementia praecox → DSM-5 separates catatonia as a separate specifier → ICD-10 retains F20.2. |
| 2. Causes | Schizophrenia predisposition + decreased GABA-A receptor function and glutamate hyperactivity are involved in the expression of catatonia; autoimmune, metabolic abnormalities, and drugs (differentiation from NMS after antipsychotic administration is important) are also causes. |
| 3. Genetics | In addition to the genetic predisposition common to schizophrenia, GABA-related genes associated with catatonia (GABA-A subunit genes) and genes associated with mood disorders (genetic overlap with bipolar disorder) have been reported. |
| 4. General epidemiology | Catatonic schizophrenia accounts for about 5-10% of all schizophrenia; the catatonia syndrome occurs in about 10% of psychiatric inpatients and is also common in mood disorders; prevalence has recently been declining (influence of advances in antipsychotics). |
| 5. Pathophysiology | Abnormal inhibition of cerebral cortical-subcortical circuits due to decreased GABA-A receptor function; excessive inhibition of the frontal-basal ganglia-thalamic circuit (frontal-BG-thalamic circuit); response to benzodiazepines is evidence for the mechanism. |
| 6. Symptoms | Two or more of catatonic stupor, excitement, waxy flexibility, rigidity, mutism, negativism, posturing, echolalia, and echopraxia. |
| 7. Signs | Waxy flexibility (wax doll sign), psychological pillow, negativism, stereotypy, Gegenhalten (resistance to passive movement); quantified with the Bush-Francis Catatonia Rating Scale (BFCRS). |
| 8. Screening | Screening of catatonia severity with the BFCRS and Rogers Catatonia Scale; systematic catatonia assessment of all patients with psychomotor abnormalities on admission; benzodiazepine response test (lorazepam test). |
| 9. Diagnosis | ICD-10 F20.2 criteria; organic catatonia (NMS, autoimmune encephalitis, metabolic abnormalities, drugs) must be excluded; differentiate from catatonia in manic/depressive episodes of bipolar disorder. |
| 10. Treatment | Benzodiazepines (lorazepam IV/IM) are first-line treatment; electroconvulsive therapy (ECT) is effective for refractory cases or catatonic excitement; caution about the risk of malignant catatonia (NMS-like) with antipsychotics. |
| 11. Prognosis | The catatonic episode itself responds well to treatment (benzodiazepines, ECT); long-term prognosis depends on the course of the underlying schizophrenia; malignant catatonia is a medical emergency with a risk of death. |
| 12. Prevention | Maintain treatment of the underlying schizophrenia; avoid precipitating drugs (antipsychotic overdose, abrupt benzodiazepine discontinuation); consider maintenance ECT for recurrent catatonia; early recognition and immediate response to NMS. |
| 13. References | Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis and Treatment. Cambridge University Press. 2003 … and 9 other papers |
The history of catatonia and catatonic schizophrenia begins with the clinical descriptions of 19th-century German psychiatry. In 1874, the German Karl Ludwig Kahlbaum first described catatonia as an independent clinical syndrome in his book 'Die Katatonie.' Kahlbaum described in detail the core symptoms of catatonia, such as motility inhibition, muscular tension, mutism, echolalia, and waxy flexibility, and argued that this syndrome is a functional disease of the nervous system. He emphasized that catatonia is a distinct diagnostic category.
Emil Kraepelin included Kahlbaum's catatonia as a subtype of dementia praecox. Kraepelin considered that the catatonic form may follow a different course from the paranoid or hebephrenic forms, but that ultimately all belong to the category of dementia praecox. Eugen Bleuler in 1911 maintained Kraepelin's view that catatonia is a phenotype of schizophrenia, while acknowledging that catatonic symptoms can also arise from psychological causes.
Until the mid-20th century, catatonic schizophrenia was diagnosed relatively commonly, but after the 1950s the introduction of antipsychotics (chlorpromazine, 1952) and benzodiazepines changed the clinical picture, and typical catatonic episodes decreased sharply. ICD-9 (1978) and DSM-III (1980) both included catatonic schizophrenia as an independent subtype. ICD-10 (1992) retained the classification as F20.2, and DSM-IV (1994) also retained the catatonic subtype.
A notable historical turning point is the change in classification in DSM-5 in 2013. DSM-5 abolished the subtypes of schizophrenia and at the same time elevated catatonia to a separate specifier that can be added to several mental disorders (schizophrenia, bipolar disorder, depressive disorders, other medical conditions). This reflects the clinical evidence that catatonia is not limited to schizophrenia but can appear in various underlying disorders. ICD-10 still retains F20.2, and this code is used in Korean clinical practice. ICD-11 (2022) also strengthened the view of catatonia as a syndrome that can occur in various underlying disorders.
The person who made the greatest contribution to modern catatonia research is the American Max Fink, who emphasized that catatonia appears more often in mood disorders (especially bipolar disorder) than in schizophrenia, and that benzodiazepines and electroconvulsive therapy (ECT) are the core treatments. This view is reflected in the current DSM-5 classification and treatment guidelines.
The cause of catatonic schizophrenia is understood from the perspective that the psychomotor syndrome of catatonia is superimposed on the general etiological basis of schizophrenia. The central mechanism of catatonia itself is decreased GABA-A receptor function, and catatonic schizophrenia is the manifestation of this against the vulnerability-stress background of schizophrenia.
Decreased GABA-A receptor function: The strongest mechanistic evidence for catatonia is the dramatic therapeutic effect of benzodiazepines (BZD, positive allosteric modulators of the GABA-A receptor). A model is proposed in which decreased GABA-A receptor function in catatonia patients disrupts inhibitory regulation of the frontal-basal ganglia-thalamic circuit, and excessive inhibition of this circuit (excessive thalamic gating) causes psychomotor retardation (stupor, waxy flexibility, mutism). When GABA-A receptor activity is restored by BZD administration, the function of this circuit normalizes and catatonic symptoms resolve rapidly.
Glutamate system: There is a hypothesis that NMDA receptor overactivity or dysregulation is involved in the catatonic excitement phase. The frequent occurrence of catatonia in acute autoimmune encephalitis (especially NMDAR antibody encephalitis) supports this hypothesis.
Causal factors common to schizophrenia: In catatonic schizophrenia, the genetic vulnerability, neurodevelopmental abnormality, and dopamine system abnormality of schizophrenia itself lie in the background. In addition, extreme psychological stress, abrupt environmental change, sleep deprivation, and substance use act as triggers of catatonic episodes.
Iatrogenic and drug-related causes: Neuroleptic malignant syndrome (NMS) caused by antipsychotics (especially first-generation high-potency drugs) is the most important in the differential diagnosis from catatonic schizophrenia. NMS is a medical emergency accompanied by high fever, muscle rigidity, autonomic instability, and altered consciousness. Abrupt discontinuation of benzodiazepines can also induce or worsen catatonia.
The genetics of catatonic schizophrenia combines the genetic predisposition of schizophrenia in general with catatonia-specific genetic factors. Research to date is moving toward understanding catatonia as a transdiagnostic syndrome appearing across schizophrenia and mood disorders rather than studying it as a trait specific to a schizophrenia subtype.
Genetic predisposition common to schizophrenia: Schizophrenia risk loci identified in GWAS also apply to catatonic schizophrenia. In particular, it has been suggested that variants in GABA signaling-related genes (GABRA1, GABRB3, and other GABA-A receptor subunit genes) may be associated with the expression of catatonia. This is consistent with decreased GABA-A function being the core mechanism of catatonia.
Genetic overlap with mood disorders: Clinical epidemiologic findings show that catatonia appears more often in bipolar disorder than in schizophrenia, and it has been suggested that genetic risk genes for bipolar disorder may be shared with the tendency toward catatonia. In particular, variants of CACNA1C (L-type calcium channel) and ANK3 (ankyrin-3) are major risk genes for bipolar disorder and may also be related to the expression of catatonia. In the schizophrenia-bipolar disorder continuum hypothesis, there is also a view that catatonic schizophrenia lies in the middle of this continuum.
Autoimmune genetic factors: In relation to catatonia of autoimmune causes such as NMDAR antibody encephalitis, it has been reported that HLA genotype (especially HLA-DQ genotype) is associated with the risk of autoantibody production. MHC region risk loci for schizophrenia may also be involved in immunological catatonia mechanisms.
Rare CNVs: There are case reports that catatonia appears more frequently in schizophrenia patients carrying neurodevelopment-related CNVs such as the 22q11.2 deletion, but large confirmatory studies are lacking. This may reflect a tendency for psychomotor abnormalities to be more prominent as neurodevelopmental impairment is greater.
The precise prevalence of catatonic schizophrenia is determined in systems using the ICD-10 subtype classification, and it accounts for about 5-10% of all schizophrenia. However, the catatonia syndrome itself occurs far more widely.
Overall prevalence of the catatonia syndrome: A meta-analysis found that the catatonia syndrome occurs in about 7-17% of psychiatric inpatients. Interestingly, the most common underlying diagnosis of catatonia is not schizophrenia but mood disorders (major depressive disorder, bipolar disorder), and catatonia is reported in about 15-25% of inpatients with mood disorders. This is the main basis on which DSM-5 separated catatonia from the schizophrenia subtype and converted it into a transdiagnostic specifier.
Age of onset and sex: Catatonic schizophrenia shows an age-of-onset distribution similar to schizophrenia in general, mainly beginning at ages 15-35. Sex differences are similar to schizophrenia in general, but the proportion of women is higher in catatonia due to underlying mood disorders.
Temporal change: After the widespread use of antipsychotics, the frequency of typical catatonic episodes (stupor, waxy flexibility, rigidity) decreased markedly. On the other hand, mild forms of catatonia (mild mutism, negativism, stereotypy) are still frequent but often unrecognized. With the spread of the Bush-Francis Catatonia Rating Scale (BFCRS) improving systematic catatonia assessment, previously unrecognized catatonia is being diagnosed more often.
Epidemiology in Korea: In Korea, F20.2 catatonic schizophrenia accounts for a relatively small share of all patients treated for schizophrenia. Emergency admission due to a catatonic episode and the risk of physical complications (pneumonia, pressure ulcers, dehydration, deep vein thrombosis) require intensive treatment. Registration for Special Copayment Reduction (V161) reduces the burden of treatment costs.
The core pathophysiology of catatonic schizophrenia is abnormal GABA-A-mediated inhibition of the frontal-basal ganglia-thalamo-cortical (BGTC) circuit.
BGTC circuit over-inhibition model: In normal voluntary movement, thalamic inhibition is reduced from the prefrontal cortex through the direct pathway of the basal ganglia (disinhibition), and movement is thereby initiated. In catatonia, decreased GABA-A receptor function causes overactivity of the indirect pathway of the basal ganglia, resulting in excessive inhibition of the thalamus (excessive thalamic gating). This excessive inhibition blocks cortico-spinal motor output and appears as motor inhibition (stupor, mutism, waxy flexibility). When a benzodiazepine restores GABA-A receptor function and normalizes this circuit, catatonic symptoms improve rapidly.
Mechanism of waxy flexibility: Waxy flexibility is the peculiar symptom of maintaining a posture passively imposed, which is explained by a dissociation between normal motor intention and muscle activation. Dysfunction of the supplementary motor area (SMA) and motor planning networks is proposed as the neurological basis of this peculiar phenomenon.
Mechanism of catatonic excitement: In contrast to stupor, in catatonic excitement hyperexcitation occurs due to glutamate hyperactivity or loss of GABA inhibition. In this state, intense purposeless motor activity (violent behavior, self-harm) appears, accompanied by autonomic instability (sweating, tachycardia). Catatonic excitement carries a risk of progressing to malignant catatonia and requires immediate management.
Malignant catatonia and NMS: Malignant catatonia and NMS are clinically difficult to distinguish. High fever, muscle rigidity, autonomic instability, altered consciousness, and elevated CK are common findings. In NMS, hypothalamic dysfunction and skeletal muscle abnormality due to dopamine D2 blockade are the core mechanism, whereas in malignant catatonia decreased GABA-A function is the core. Both conditions are medical emergencies requiring immediate discontinuation of antipsychotics, supportive treatment, and benzodiazepines and/or ECT.
The clinical symptoms of catatonic schizophrenia center on psychomotor disturbance, and inhibitory symptom clusters (hypomotor features) and excitement symptom clusters (hypermotor features) may alternate or coexist.
Catatonic stupor: A state of unresponsiveness to external stimuli and absence of spontaneous movement while remaining awake. The eyes are open but fixed gaze, inability to communicate, and refusal of food and drink appear. If prolonged, there is a high risk of physical complications such as dehydration, malnutrition, pneumonia, pressure ulcers, and deep vein thrombosis.
Waxy flexibility (flexibilitas cerea): A symptom of maintaining a posture when the limbs are passively moved, characterized by flexibly assuming postures like a wax (beeswax) doll. This is a state with neither resistance nor active participation and is the most characteristic symptom of catatonic schizophrenia.
Mutism: A state in which spontaneous speech is completely lost; when necessary, the patient may attempt to communicate by writing or nodding. Language comprehension may be preserved, and some patients recall their experiences during the episode in detail after recovery from catatonia.
Negativism: A symptom of actively resisting instructions or passive movement. It appears in various forms, such as refusing food, clamping the mouth shut, resisting eye opening, and resisting movement of the limbs. Gegenhalten (resistance to passive movement, a phenomenon of resisting in proportion to the examiner's force) is a characteristic physical sign.
Posturing: A symptom of voluntarily assuming and maintaining an uncomfortable or bizarre posture for a long time. It appears in forms such as holding up only one arm, squatting, or maintaining bizarre hand movements.
Echolalia and echopraxia: A symptom of repeating the other person's words exactly (echolalia) or imitating the other person's actions (echopraxia). This occurs automatically rather than as the patient's own intentional behavior.
Catatonic excitement: An excited state with purposeless intense motor activity, impulsive and violent behavior, self-harm, and extreme anxiety, which may alternate with the stuporous state. There is a risk of progression to malignant catatonia, so immediate management is needed.
The physical and psychiatric signs of catatonic schizophrenia are concentrated in psychomotor abnormalities and are quantified with systematic catatonia assessment scales.
Wax doll sign: When the examiner passively moves the patient's limbs, the patient maintains that posture. It is characterized by a peculiar passivity without resistance, flexible like a wax doll yet maintaining the posture.
Psychological pillow: A symptom in which, after the head of a patient lying down is raised and the support is removed, the head remains suspended 5-10 cm in the air without a pillow. It is a classic and characteristic sign of catatonic schizophrenia.
Gegenhalten (resistance to passive movement): A phenomenon in which, when the examiner tries to move the patient's limbs, the patient resists in proportion to the examiner's force. It is automatic rather than voluntary resistance and is distinguished from ordinary muscle rigidity.
Stereotypy: Purposeless repetitive movements (hand waving, rocking, foot stamping, etc.) appear in the excitement symptom cluster of catatonia.
Bush-Francis Catatonia Rating Scale (BFCRS): A standardized scale that rates catatonia severity on a 0-3 scale across 23 items. It assesses the presence and duration of each symptom, and a total score of 2 or more (or positivity on any 3 or more specific items) is used as the criterion for clinically significant catatonia. For screening purposes, a 14-item screening version of the BFCRS is also used.
Laboratory tests and vital signs: In catatonic stupor, signs of physical complications such as dehydration (elevated serum sodium and BUN), malnutrition (decreased albumin), and aspiration pneumonia (abnormal chest X-ray) should be monitored. In malignant catatonia, high fever (> 38.5°C), tachycardia, unstable blood pressure, and marked elevation of creatine kinase (CK) appear.
Systematic assessment for early detection of catatonic schizophrenia and the catatonia syndrome is essential in psychiatric practice.
BFCRS screening assessment: Applying the BFCRS screening version (14 items) at admission to all patients with psychomotor abnormalities (stupor, mutism, negativism, stereotypy, hyperactivity) is recommended. There are study results showing that systematic application of the BFCRS to all psychiatric inpatients is useful for detecting hidden catatonia.
Lorazepam challenge test: When catatonia is clinically suspected, if catatonic symptoms improve markedly within 5-30 minutes after lorazepam 1-2 mg intramuscularly or intravenously, catatonia is diagnosed and treatment response is confirmed at the same time. This test is a practical method that performs diagnosis and treatment simultaneously and is useful in emergency settings.
Monitoring for NMS differentiation: When fever, muscle rigidity, and altered consciousness appear in a patient receiving antipsychotics, the possibility of NMS must be evaluated immediately. A monitoring system including vital signs, CK, electrolytes, and urine myoglobin tests is needed.
Autoimmune encephalitis screening: In first-episode or atypical catatonia, systematic testing including serum and CSF neuronal antibody tests, brain MRI (FLAIR abnormality), and EEG (abnormal brain waves) is needed to exclude autoimmune encephalitis (NMDAR antibody, LGI1 antibody, etc.).
The diagnosis of catatonic schizophrenia proceeds in stages: meeting the general criteria for schizophrenia, confirming the catatonia syndrome, and excluding organic and iatrogenic causes.
ICD-10 F20.2 diagnostic criteria: While meeting the general criteria for schizophrenia (F20), prominent symptoms among the following catatonic symptoms must dominate the clinical picture: ① stupor or mutism, ② excitement, ③ posturing, ④ negativism, ⑤ rigidity, ⑥ waxy flexibility (flexibilitas cerea), ⑦ automatic obedience or verbigeration. Catatonic symptoms must appear together with other symptoms of schizophrenia (delusions, hallucinations).
Application of DSM-5 criteria: DSM-5 diagnoses schizophrenia + the catatonia specifier, and catatonia is diagnosed when 3 or more of the following 12 symptoms apply: stupor, catalepsy (waxy flexibility), waxy flexibility, mutism, negativism, posturing, mannerism, stereotypy, agitation, grimacing, echolalia, echopraxia.
Differential diagnosis: ① NMS (neuroleptic malignant syndrome): history of antipsychotic use, fever, elevated CK, and autonomic instability are the distinguishing points. ② Autoimmune encephalitis: excluded by neuronal antibody tests such as NMDAR antibody and LGI1 antibody, brain MRI, and EEG. ③ Mood disorder-related catatonia: catatonia appearing in manic/depressive episodes of bipolar disorder and in major depressive disorder. ④ Metabolic abnormalities: psychomotor abnormality due to hyponatremia, hypoglycemia, hepatic encephalopathy, and serotonin syndrome. ⑤ Locked-in syndrome: motor incapacity due to a brainstem lesion (excluded by brain MRI).
Essential tests: blood (CK, electrolytes, BMP, liver function, thyroid, autoimmune antibodies), urine drug screen, brain MRI, EEG, serum and CSF neuronal antibody tests (in atypical cases).
Treatment of catatonic schizophrenia consists of acute treatment of the catatonic episode and long-term treatment of the underlying schizophrenia. The first-line treatment of catatonia itself is benzodiazepines, and ECT is effective for treatment resistance.
Benzodiazepines (BZD) — first-line treatment: Intravenous or intramuscular lorazepam (1-2 mg, at intervals of 4-8 hours) is the first-line treatment for catatonia. In most catatonia patients, dramatic improvement appears within hours of BZD administration. Monitoring for sedation and respiratory depression is needed, and when oral intake becomes possible, switch to oral lorazepam (1-2 mg, 2-3 times a day). BZDs are also effective for psychomotor abnormalities due to antipsychotic adverse effects such as akathisia and parkinsonism.
Electroconvulsive therapy (ECT): ECT is effective for treatment-resistant catatonia that does not respond sufficiently to BZD, malignant catatonia, and catatonic excitement. ECT acts by directly correcting the GABA-A and glutamate abnormalities of catatonia, and marked improvement is usually seen after 6-12 treatments. Maintenance ECT (1-2 times per month) can be considered in patients with recurrent catatonia.
Cautious use of antipsychotics: The role of antipsychotics in catatonic schizophrenia is complex. First-generation high-potency antipsychotics (haloperidol, etc.) can worsen catatonia or induce NMS, so caution is needed in their use. After catatonia has resolved, second-generation antipsychotics are started at a low dose and applied carefully to treat the underlying schizophrenia. There are case reports that clozapine is effective for both catatonia and the underlying schizophrenia in treatment-resistant catatonic schizophrenia.
Supportive treatment: In patients in stupor, sufficient fluid and nutrition supply (nasogastric tube or intravenous nutrition if oral intake is not possible), pressure ulcer prevention (position changes), pneumonia prevention (oral hygiene, aspiration precautions), and deep vein thrombosis prevention (early mobilization, consideration of anticoagulants) are essential. Malignant catatonia requires intensive monitoring at the intensive care unit level.
The prognosis of catatonic schizophrenia should be understood in two dimensions: the short-term prognosis of the catatonic episode itself and the long-term prognosis of the underlying schizophrenia.
Short-term prognosis of the catatonic episode: The response to BZD and/or ECT is generally good, and with appropriate treatment catatonic symptoms resolve within days to weeks. The BZD response rate is reported at about 70-80%, and adding ECT in nonresponders brings the cumulative response rate to 90% or more. Malignant catatonia can have its mortality lowered if recognized early and treated with discontinuation of antipsychotics, active supportive treatment, and ECT, but with delayed treatment mortality reaches 10-15%.
Long-term prognosis: The long-term prognosis after a catatonic episode depends on the course of the underlying schizophrenia. There are reports that the long-term functional prognosis of catatonic schizophrenia is somewhat better than that of schizophrenia alone, but the risk of recurrent catatonic episodes and the negative symptoms and cognitive deficits of the underlying schizophrenia accumulate. In some patients, catatonia tends to recur repeatedly and become chronic.
Effect of physical complications on prognosis: If catatonic stupor persists, there is a risk of life-threatening complications such as aspiration pneumonia, sepsis, deep vein thrombosis, and pulmonary embolism. When these physical complications occur, mortality and morbidity increase greatly. Early recognition and prompt initiation of treatment are key to preventing physical complications.
Risk of recurrence: Catatonia tends to recur, and the risk of recurrence is high especially on exposure to precipitating factors (change of antipsychotics, discontinuation of benzodiazepines, severe stress). Maintenance BZD or maintenance ECT is considered in patients at high risk of recurrence.
Prevention of catatonic schizophrenia consists of maintaining treatment of the underlying schizophrenia and preventing recurrence of catatonic episodes.
Maintaining treatment of the underlying schizophrenia: Preventing schizophrenia relapse with maintenance antipsychotic therapy is the basis for preventing recurrence of catatonic episodes. Use of LAI (long-acting injectables) is recommended to maintain medication adherence. There are reports that clozapine is also effective for preventing recurrence of catatonia in treatment-resistant schizophrenia.
Avoiding precipitating factors: Factors that can induce or worsen catatonia are avoided. Abrupt dose escalation of high-potency first-generation antipsychotics, abrupt discontinuation of benzodiazepines, severe acute stress, and sleep deprivation are risk factors. In particular, recurrence of catatonia should be monitored when antipsychotics are changed.
Maintenance ECT for recurrent catatonia: In patients in whom maintenance with BZD alone is difficult or who have frequent catatonia recurrences, maintenance ECT (1-2 times per month) is considered as a relapse prevention strategy.
NMS prevention and early recognition: When fever, muscle rigidity, and altered consciousness appear in a patient using antipsychotics, the possibility of NMS is evaluated immediately and the antipsychotic is discontinued. Close monitoring is needed in high-risk situations (use of high-dose drugs, dehydration, infection, preexisting dystonia).
Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis and Treatment. Cambridge University Press. 2003. ISBN: 978-0521532136.
Sienaert P, Dhossche DM, Vancampfort D, De Hert M, Gazdag G. A clinical review of the treatment of catatonia. Front Psychiatry. 2014;5:181. DOI: 10.3389/fpsyt.2014.00181. PMID: 25566090.
Walther S, Strik W. Catatonia. CNS Spectr. 2016;21(4):341-348. DOI: 10.1017/S1092852916000262. PMID: 27374825.
Tandon R, Heckers S, Bustillo J, et al. Catatonia in DSM-5. Schizophr Res. 2013;150(1):26-30. DOI: 10.1016/j.schres.2013.04.034. PMID: 23773769.
Ungvari GS, Caroff SN, Gerevich J. The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders. Schizophr Bull. 2010;36(2):231-238. DOI: 10.1093/schbul/sbp105. PMID: 19776154.
Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand. 1996;93(2):129-136. DOI: 10.1111/j.1600-0447.1996.tb09814.x. PMID: 8686484.
Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. DOI: 10.1038/nrdp.2015.67. PMID: 27189524.
Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399(10323):473-486. DOI: 10.1016/S0140-6736(21)01730-X. PMID: 35093236.
Rasmussen SA, Mazurek MF, Rosebush PI. Catatonia: our current understanding of its diagnosis, treatment and pathophysiology. World J Psychiatry. 2016;6(4):391-398. DOI: 10.5498/wjp.v6.i4.391. PMID: 28078203.
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. NICE guideline CG178. 2014 (updated 2019). Available at: https://www.nice.org.uk/guidance/cg178.